pembrolizumab,belzutifan,cabozantinib
exelixis,merck
['1447o', 'cabozantinib', 'belzutifan', 'lite,spark-003', 'rcc,(-irccs),(-srcc),(-urcc)']
#esmo22 abs#1447o: ph2 trial #litespark-003 cohort 1 of belzutifan + cabozantinib achieved orr of 57% in 1l #mrcc, mpfs was 30.3 mo, mos not reached, with 37% had a grade 3 trae. #jaimemerchan 
@Huntsmancancer fellow, @SYSU & @UofT alumnus, #stargazer, #aurora chaser